1
|
Diarra A, Gachet B, Beltrand E, Dartus J, Loiez C, Fiaux E, Patoz P, Robineau O, Senneville E. Outcomes in orthopedic device infections due to Streptococcus agalactiae: a retrospective cohort study. BMC Infect Dis 2024; 24:424. [PMID: 38649829 PMCID: PMC11034090 DOI: 10.1186/s12879-024-09175-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 02/26/2024] [Indexed: 04/25/2024] Open
Abstract
BACKGROUND Group B streptococci (Streptococcus agalactiae) (GBS) is a rare cause of prosthetic joint infection (PJI) occurring in patients with comorbidities and seems to be associated with a poor outcome. Depiction of GBS PJI is scarce in the literature. METHODS A retrospective survey in 2 referral centers for bone joint infections was done Patients with a history of PJI associated with GBS between 2014 and 2019 were included. A descriptive analysis of treatment failure was done. Risk factors of treatment failure were assessed. RESULTS We included 61 patients. Among them, 41 had monomicrobial (67%) infections. The median duration of follow-up was 2 years (interquartile range 2.35) Hypertension, obesity, and diabetes mellitus were the most reported comorbidities (49%, 50%, and 36% respectively). Death was observed in 6 individuals (10%) during the initial management. The rate of success was 63% (26/41). Removal of the material was not associated with remission (p = 0.5). We did not find a specific antibiotic regimen associated with a better outcome. CONCLUSION The results show that S. agalactiae PJIs are associated with high rates of comorbidities and a high treatment failure rate with no optimal treatment so far.
Collapse
Affiliation(s)
- Ava Diarra
- Department of Infectious Diseases, Hôpital Gustave Dron, 135 rue du Président Coty, F-59200, Tourcoing, France
| | - Benoit Gachet
- Department of Infectious Diseases, Hôpital Gustave Dron, 135 rue du Président Coty, F-59200, Tourcoing, France
- ULR 2694 - Évaluation des technologies de santé et des pratiques médicales, Univ. Lille, F-59000, Lille, France
| | - Eric Beltrand
- Department of Orthopedic Surgery, Hôpital Gustave Dron, Tourcoing, France
| | - Julien Dartus
- Department of Orthopedic Surgery, CHRU de Lille, Lille, France
| | - Caroline Loiez
- Department of Bacteriology, CHRU de Lille, Tourcoing, France
| | - Elise Fiaux
- Department of Infectious Diseases, Centre Hospitalo-Universitaire de Rouen, Rouen, France
| | - Pierre Patoz
- Department of Bacteriology, Gustave Dron Hospital, Lille University, Lille, France
| | - Olivier Robineau
- Department of Infectious Diseases, Hôpital Gustave Dron, 135 rue du Président Coty, F-59200, Tourcoing, France
- ULR 2694 - Évaluation des technologies de santé et des pratiques médicales, Univ. Lille, F-59000, Lille, France
| | - Eric Senneville
- Department of Infectious Diseases, Hôpital Gustave Dron, 135 rue du Président Coty, F-59200, Tourcoing, France.
- ULR 2694 - Évaluation des technologies de santé et des pratiques médicales, Univ. Lille, F-59000, Lille, France.
| |
Collapse
|
2
|
Caulier T, Senneville E, Sobocinski J, Leroy O, Patoz P, Blondiaux N, Georges H, Pierre-Yves D, d'Elia P, Robineau O. Burden of Candida-related vascular graft infection: a nested-case control study. Infection 2024:10.1007/s15010-023-02172-y. [PMID: 38329687 DOI: 10.1007/s15010-023-02172-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 12/29/2023] [Indexed: 02/09/2024]
Abstract
PURPOSE We aimed to assess risk factors of candida-related Vascular Graft Infections (VGIs). METHODS We did a case-control study (1:4) matched by age and year of infection, nested in a cohort of patient with a history of VGIs. Cases were defined by a positive culture for Candida spp. in biological samples and controls were defined by a positive culture for bacterial strains only in biological samples. Risk factors for Candida-related VGIs were investigated using multivariate logistic regression. Mortality were compared using survival analysis. RESULTS 16 Candida-related VGIs were matched to 64 bacterial-related VGIs. The two groups were comparable regarding medical history and clinical presentation. Candida-related VGIs were associated with bacterial strains in 88% (14/16). Gas/fluid-containing collection on abdominal CT scan and the presence of an aortic endoprosthesis were risk factors for Candida spp.-related VGIs [RRa 10.43 [1.81-60.21] p = 0.009 RRa and 6.46 [1.17-35.73] p = 0.03, respectively]. Candida-related VGIs were associated with a higher mortality when compared to bacterial-related VGIs (p = 0.002). CONCLUSIONS Candida-related VGIs are severe. Early markers of Candida spp. infection are needed to improve their outcome. The suspicion of aortic endoprosthesis infection may necessitate probabilistic treatment with antifungal agents.
Collapse
Affiliation(s)
| | - Eric Senneville
- Service Universitaire Des Maladies Infectieuses Et du Voyageur, Centre Hospitalier Gustave Dron, 59210, Tourcoing, France
- University of Lille, CHU Lille, ULR 2694, METRICS, Évaluation Des Technologies de Santé Et Des Pratiques Médicales, 59000, Lille, France
| | | | | | | | - Nicolas Blondiaux
- Service de Biologie, CH de Tourcoing, France
- University of Lille, CNRS, Inserm, Institut Pasteur de Lille, U1019, UMR9017 Center for Infection and Immunity of Lille, Lille, France
| | | | | | | | - Olivier Robineau
- Service Universitaire Des Maladies Infectieuses Et du Voyageur, Centre Hospitalier Gustave Dron, 59210, Tourcoing, France.
- University of Lille, CHU Lille, ULR 2694, METRICS, Évaluation Des Technologies de Santé Et Des Pratiques Médicales, 59000, Lille, France.
- INSERM u1136, Institut Pierre Louis de Santé Publique, Paris, France.
| |
Collapse
|
3
|
Boucher A, Pradier M, Lafondesmurs B, Thill P, Patoz P, Blondiaux N, Joulie D, Hennart B, Robineau O, Senneville E. Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis. Infect Dis Now 2024; 54:104835. [PMID: 37972818 DOI: 10.1016/j.idnow.2023.104835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 11/09/2023] [Accepted: 11/13/2023] [Indexed: 11/19/2023]
Abstract
OBJECTIVES We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation. PATIENTS AND METHODS Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin. RESULTS Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission. CONCLUSIONS In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.
Collapse
Affiliation(s)
- Anne Boucher
- Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France.
| | - Maxime Pradier
- Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France
| | - Barthelemy Lafondesmurs
- Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France
| | - Pauline Thill
- Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France
| | - Pierre Patoz
- Laboratoire de Microbiologie, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France
| | - Nicolas Blondiaux
- Laboratoire de Microbiologie, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France
| | - Donatienne Joulie
- Service de Chirurgie Orthopédique et Traumatologique, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France
| | - Benjamin Hennart
- Service de Toxicologie-Génopathies, Centre Hospitalier Universitaire de Lille, F-59000, Lille, France
| | - Olivier Robineau
- Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France; Université de Lille, ULR 2694 - METRICS : Évaluation des technologies de santé et des pratiques médicales, F-59000, Lille, France
| | - Eric Senneville
- Service Universitaire des maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, F-59200, Tourcoing, France; Université de Lille, ULR 2694 - METRICS : Évaluation des technologies de santé et des pratiques médicales, F-59000, Lille, France
| |
Collapse
|
4
|
Le Berre C, Houard M, Vachée A, Georges H, Wallet F, Patoz P, Herbecq P, Nseir S, Delannoy PY, Meybeck A. Antibiotic Prescriptions in Critically Ill Patients with Bloodstream Infection Due to ESBL-Producing Enterobacteriaceae: Compliance with the French Guidelines for the Treatment of Infections with Third-Generation Cephalosporin-Resistant Enterobacteriaceae-A Multicentric Retrospective Cohort Study. Microorganisms 2023; 11:2676. [PMID: 38004688 PMCID: PMC10673552 DOI: 10.3390/microorganisms11112676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 10/18/2023] [Accepted: 10/23/2023] [Indexed: 11/26/2023] Open
Abstract
National and international guidelines were recently published regarding the treatment of Enterobacteriaceae resistant to third-generation cephalosporins infections. We aimed to assess the implementation of the French guidelines in critically ill patients suffering from extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infection (ESBL-E BSI). We conducted a retrospective observational cohort study in the ICU of three French hospitals. Patients treated between 2018 and 2022 for ESBL-E BSI were included. The primary assessment criterion was the proportion of adequate empirical carbapenem prescriptions, defined as prescriptions consistent with the French guidelines. Among the 185 included patients, 175 received an empirical anti-biotherapy within 24 h of ESBL-E BSI onset, with a carbapenem for 100 of them. The proportion of carbapenem prescriptions consistent with the guidelines was 81%. Inconsistent prescriptions were due to a lack of prescriptions of a carbapenem, while it was recommended in 25% of cases. The only factor independently associated with adequate empirical carbapenem prescription was ESBL-E colonization (OR: 107.921 [9.303-1251.910], p = 0.0002). The initial empirical anti-biotherapy was found to be appropriate in 83/98 patients (85%) receiving anti-biotherapy in line with the guidelines and in 56/77 (73%) patients receiving inadequate anti-biotherapy (p = 0.06). Our results illustrate the willingness of intensivists to spare carbapenems. Promoting implementation of the guidelines could improve the proportion of initial appropriate anti-biotherapy in critically ill patients with ESBL-E BSI.
Collapse
Affiliation(s)
- Camille Le Berre
- Service de Réanimation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Président Coty, 59200 Tourcoing, France; (C.L.B.); (H.G.); (P.-Y.D.)
| | - Marion Houard
- Service de Réanimation Médicale, CHRU de Lille, 2 Avenue Oscar Lambret, 59000 Lille, France; (M.H.); (S.N.)
| | - Anne Vachée
- Laboratoire de Microbiologie, Centre Hospitalier de Roubaix, 11 Boulevard Lacordaire, 59100 Roubaix, France;
| | - Hugues Georges
- Service de Réanimation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Président Coty, 59200 Tourcoing, France; (C.L.B.); (H.G.); (P.-Y.D.)
| | - Frederic Wallet
- Laboratoire de Microbiologie, CHRU de Lille, 2 Avenue Oscar Lambret, 59000 Lille, France;
| | - Pierre Patoz
- Laboratoire de Microbiologie, Centre Hospitalier de Tourcoing, 135 Rue du Président Coty, 59200 Tourcoing, France;
| | - Patrick Herbecq
- Service de Réanimation, Centre Hospitalier de Roubaix, 11 Boulevard Lacordaire, 59100 Roubaix, France;
| | - Saad Nseir
- Service de Réanimation Médicale, CHRU de Lille, 2 Avenue Oscar Lambret, 59000 Lille, France; (M.H.); (S.N.)
| | - Pierre-Yves Delannoy
- Service de Réanimation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Président Coty, 59200 Tourcoing, France; (C.L.B.); (H.G.); (P.-Y.D.)
| | - Agnès Meybeck
- Service de Réanimation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Président Coty, 59200 Tourcoing, France; (C.L.B.); (H.G.); (P.-Y.D.)
| |
Collapse
|
5
|
Milliere L, Loïez C, Patoz P, Charlet A, Duployez C, Wallet F. Apyretic pulmonary oedema revealing Cardiobacterium hominis endocarditis: case report and review of literature. IDCases 2022; 29:e01506. [PMID: 35669524 PMCID: PMC9166381 DOI: 10.1016/j.idcr.2022.e01506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 04/21/2022] [Accepted: 05/16/2022] [Indexed: 11/16/2022] Open
Abstract
Cardiobacterium hominis is a member of the HACEK group of bacteria, responsible for infective endocarditis, mainly in patients with damaged or prosthetic valves. The low virulence of this organism can explain the insidious presentation and subacute or chronic progression of C. hominis infective endocarditis. Here, a 41-year-old man with a past history of surgery for a Waldhausen type aortic coarctation was hospitalised with dyspnea and chest pains revealing an acute pulmonary oedema, without fever. Transesophageal echocardiography indicated a 20 mm vegetation on biscuspid aortic valve. Six sets of blood culture were positive with Cardiobacterium hominis. In case of lack of fever, the diagnosis of infectious endocarditis is difficult because other symptoms are non-specific and biological markers of inflammatory syndrome are quiet or non-existent. This is the first case of C. hominis infectious endocarditis with a clinical presentation of acute pulmonary oedema in the literature. We report here an apyretic pulmonary oedema revealing C. hominis endocarditis and a review of the literature on apyretic infective endocarditis due to C. hominis.
Collapse
Affiliation(s)
- Laurine Milliere
- Laboratoire Bactériologie Hygiène, CHU Lille, Univ Lille, 59037 Lille, France
- Corresponding author.
| | - Caroline Loïez
- Laboratoire Bactériologie Hygiène, CHU Lille, Univ Lille, 59037 Lille, France
| | - Pierre Patoz
- Laboratoire de biologie médicale, CH Dron, 59200 Tourcoing, France
| | - Audrey Charlet
- Laboratoire Bactériologie Hygiène, CHU Lille, Univ Lille, 59037 Lille, France
| | - Claire Duployez
- Laboratoire Bactériologie Hygiène, CHU Lille, Univ Lille, 59037 Lille, France
| | - Frédéric Wallet
- Laboratoire Bactériologie Hygiène, CHU Lille, Univ Lille, 59037 Lille, France
| |
Collapse
|
6
|
Thill P, Robineau O, Roosen G, Patoz P, Gachet B, Lafon-Desmurs B, Tetart M, Nadji S, Senneville E, Blondiaux N. Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections. J Antimicrob Chemother 2022; 77:1036-1040. [PMID: 35028671 DOI: 10.1093/jac/dkab486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Accepted: 12/08/2021] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Staphylococci account for approximately 60% of periprosthetic joint infections (PJIs). Rifampicin (RMP) combination therapy is generally considered to be the treatment of choice for staphylococcal PJIs but carries an important risk of adverse events and drug-drug interactions. Rifabutin (RFB) shares many of the properties of rifampicin but causes fewer adverse events. OBJECTIVES To compare the minimal inhibitory concentration (MIC), the minimum bactericidal concentrations (MBC), and the minimum biofilm eradication concentrations (MBEC) of rifabutin and rifampicin for staphylococcal clinical strains isolated from PJIs. METHODS 132 clinical strains of rifampicin-susceptible staphylococci [51 Staphylococcus aureus (SA), 48 Staphylococcus epidermidis (SE) and 33 other coagulase-negative staphylococci (CoNS)] were studied. The MBC and the MBEC were determined using the MBEC® Assay for rifabutin and rifampicin and were compared. RESULTS When compared with the rifampicin MIC median value, the rifabutin MIC median value was significantly higher for SA (P < 0.05), but there was no statistically significant difference for SE (P = 0.25) and CoNS (P = 0.29). The rifabutin MBC median value was significantly higher than that of rifampicin for SA (P = 0.003) and was lower for SE (P = 0.003) and CoNS (P = 0.03). Rifabutin MBEC median value was statistically lower than that of rifampicin for all strains tested. CONCLUSIONS Using the determination of MBEC values, our study suggests that rifabutin is more effective than rifampicin against clinical strains of Staphylococcus spp. obtained from PJIs. Using MBECs instead of MICs seems to be of interest when considering biofilms. In vivo higher efficacy of rifabutin when compared with rifampicin needs to be confirmed.
Collapse
Affiliation(s)
- Pauline Thill
- Department of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France
| | - Olivier Robineau
- Department of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France.,EA2694, Univ Lille, Centre Hospitalier de Tourcoing, Tourcoing, France
| | - Gabrielle Roosen
- Department of Bacteriology, Hospital of Tourcoing, Tourcoing, France
| | - Pierre Patoz
- Department of Bacteriology, Hospital of Tourcoing, Tourcoing, France
| | - Benoit Gachet
- Department of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France.,EA2694, Univ Lille, Centre Hospitalier de Tourcoing, Tourcoing, France
| | | | - Macha Tetart
- Department of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France
| | - Safia Nadji
- Department of Bacteriology, Hospital of Tourcoing, Tourcoing, France
| | - Eric Senneville
- Department of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France.,EA2694, Univ Lille, Centre Hospitalier de Tourcoing, Tourcoing, France
| | - Nicolas Blondiaux
- Department of Bacteriology, Hospital of Tourcoing, Tourcoing, France.,Univ. Lille, CNRS, Inserm, Institut Pasteur de Lille, U1019 - UMR9017 Center for Infection and Immunity of Lille, Lille, France
| |
Collapse
|
7
|
Meybeck A, Huleux T, Tétart M, Thill P, Derdour V, Bocket L, Alidjinou EK, Patoz P, Robineau O, Ajana F. History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic. Microorganisms 2021; 9:microorganisms9122491. [PMID: 34946093 PMCID: PMC8705918 DOI: 10.3390/microorganisms9122491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 11/11/2021] [Accepted: 11/18/2021] [Indexed: 11/16/2022] Open
Abstract
To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed a SARS-CoV-2 serology. Among the 600 PLWHIV included, 16 have been infected with SARS-CoV-2. Symptoms consistent with COVID-19 were frequent both in SARS-CoV-2 positive and negative patients (67% vs. 32%, p = 0.02). Among SARS-CoV-2 infected patients, one (6%) has been hospitalized and five (31%) have been asymptomatic. Close contact with a confirmed COVID-19 case was the only factor associated with COVID-19 acquisition (40% vs. 13%, p = 0.01). The prevalence of COVID-19 in PLWHIV was 2.5%, half of the overall population estimate after the first wave of the pandemic in France. In conclusion, proportion of asymptomatic COVID-19 was high in PLWHIV. The prevalence of COVID-19 in PLWHIV was two times lower than in the general population.
Collapse
Affiliation(s)
- Agnès Meybeck
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
- Correspondence: ; Tel.: +33-320694605
| | - Thomas Huleux
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| | - Macha Tétart
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| | - Pauline Thill
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| | - Vincent Derdour
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| | - Laurence Bocket
- Laboratoire de Virologie, CHRU de Lille, 59000 Lille, France; (L.B.); (E.K.A.)
| | | | - Pierre Patoz
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| | - Olivier Robineau
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| | - Faiza Ajana
- Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France; (T.H.); (M.T.); (P.T.); (V.D.); (P.P.); (O.R.); (F.A.)
| |
Collapse
|
8
|
Tinévez C, Velardo F, Ranc AG, Dubois D, Pailhoriès H, Codde C, Join-Lambert O, Gras E, Corvec S, Neuwirth C, Melenotte C, Dorel M, Lagneaux AS, Pichon M, Doat V, Fournier D, Lemaignen A, Bouard L, Patoz P, Hery-Arnaud G, Lemaitre N, Couzigou C, Guillard T, Recalt E, Bille E, Belaroussi Y, Neau D, Cazanave C, Lehours P, Puges M. Retrospective multicentric study on Campylobacter spp. bacteremia in France: the Campylobacteremia study. Clin Infect Dis 2021; 75:702-709. [PMID: 34849656 DOI: 10.1093/cid/ciab983] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Campylobacter spp. bacteremia is a severe infection. A nationwide 5-year retrospective study was conducted to characterize its clinical features and prognostic factors. METHODS Patients diagnosed with Campylobacter spp. bacteremia in 37 French hospitals participating in the surveillance network of the National Reference Center for Campylobacter and Helicobacter were included from January 1, 2015, to December 31, 2019. The goal was to analyze the effects of a delay of appropriate antibiotic therapy and other risk factors on 30-day mortality, antibiotic resistance, patient characteristics and prognosis according to the Campylobacter species. FINDINGS Among the 592 patients, Campylobacter jejuni and Campylobacter fetus were the most commonly identified species (42.9 and 42.6%, respectively). The patients were elderly (median age 68 years), and most had underlying conditions, mainly immunodepression (43.4%), hematologic malignancies (25.9%), solid neoplasms (23%) and diabetes (22.3%). C. jejuni and Campylobacter coli were associated with gastrointestinal signs, and C. fetus was associated with secondary localizations. Among the 80 patients (13.5%) with secondary localizations, 12 had endocarditis, 38 vascular, 24 osteo-articular and 9 ascitic fluid infections. The thirty-day mortality rate was 11.7%, and an appropriate antibiotic treatment was independently associated with 30-day survival (odds ratio [OR]=0.47, 95% CI [0.24-0.93], p=0.03). The median efficient therapy initiation delay was quite short (2 days, IQR [0-4]) but it had no significant impact on 30-day mortality (p=0.78). INTERPRETATION Campylobacter spp. bacteremia mainly occurred in elderly immunocompromised individuals with variable clinical presentations according to the species involved. Appropriate antimicrobial therapy was associated with improved 30-day survival.
Collapse
Affiliation(s)
- Claire Tinévez
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | - Fanny Velardo
- INSERM, Bordeaux Population Health Research Center, ISPED, University of Bordeaux, F-33000 Bordeaux, France
| | - Anne-Gaëlle Ranc
- CHU de Lyon Sud, Bacteriology Department, F-69310 Pierre-Bénite, France
| | - Damien Dubois
- CHU de Toulouse, Bacteriology Department, F-31059 Toulouse, France
| | | | - Cyrielle Codde
- CHU de Limoges, Infectious and Tropical Diseases Department, F-87000 Limoges, France
| | | | - Emmanuelle Gras
- Hôpital Européen Georges-Pompidou, Infectious and Tropical Diseases Department, F-75015 Paris, France
| | - Stéphane Corvec
- CHU de Nantes, Bacteriology Department, F-44093 Nantes, France
| | | | - Cléa Melenotte
- CHU de Marseille, Bacteriology Department, F-13005 Marseille, France
| | - Marie Dorel
- CHU de Rennes, Infectious Diseases and Intensive Care Department, F-35033 Rennes, France
| | | | - Maxime Pichon
- CHU de Poitiers, Infectious Agents Department, Bacteriology, F-86021 Poitiers, France
| | - Violaine Doat
- CH Pierre Oudot, Biology Department, F-38300 Bourguoin-Jallieu, France
| | - Damien Fournier
- CHU de Besançon, Bacteriology Department, F-25000 Besançon, France
| | - Adrien Lemaignen
- CHRU de Tours, Infectious and Tropical Diseases Department, F-37000 Tours, France
| | - Leslie Bouard
- CHD Vendée, Biology Department, F-85000 La Roche-Sur-Yon, France
| | - Pierre Patoz
- CH de Tourcoing, Biology Department, F-59208 Tourcoing, France
| | | | - Nadine Lemaitre
- CHU d'Amiens, Bacteriology Department, F-80000 Amiens, France
| | | | - Thomas Guillard
- CHU de Reims, Bacteriology Department, F-51092 Reims, France
| | - Elise Recalt
- CHU de Strasbourg, Bacteriology Department, F-67200 Strasbourg, France
| | - Emmanuelle Bille
- CH Necker-Enfants malades, Bacteriology Department, F-75015 Paris, France
| | - Yaniss Belaroussi
- INSERM, Bordeaux Population Health Research Center, ISPED, University of Bordeaux, F-33000 Bordeaux, France
| | - Didier Neau
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | - Charles Cazanave
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | - Philippe Lehours
- CHU de Bordeaux, National Reference Center for Campylobacter and Helicobacter, Bacteriology Department, F-33000 Bordeaux, France.,Univ. Bordeaux, INSERM, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, 33076, Bordeaux, France
| | - Mathilde Puges
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | | |
Collapse
|
9
|
Coehlo A, Robineau O, Titecat M, Blondiaux N, Dezeque H, Patoz P, Loiez C, Putman S, Beltrand E, Migaud H, Senneville E. Fully oral targeted antibiotic therapy for Gram-positive cocci-related periprosthetic joint infections: a real-life before and after study. J Antimicrob Chemother 2021; 76:3033-3036. [PMID: 34406411 DOI: 10.1093/jac/dkab271] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Accepted: 07/07/2021] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The optimal length of the intravenous antibiotic treatment of periprosthetic joint infections (PJIs) generally ranges from one to six weeks and is a matter of debate. Most antibiotics active against Gram-positive cocci (GPC) exhibit both high oral bioavailability and bone diffusion. Thus, early oral therapy may be a reasonable option in GPC-related PJIs. METHODS A 2 year before and after monocentric study that aimed to compare two antibiotic strategies. Empirical intravenous postoperative antibiotic treatment was followed by 7 to 10 days of intravenous targeted therapy ('before' group) or by full orally targeted antibiotic treatment ('after' group). The primary outcome was a treatment failure during follow-up. RESULTS A total of 93 patients were analysed, 43 and 50 in the before and the after groups, respectively. Both groups were comparable in terms of surgical procedures, comorbidities, microbiological documentation and infection site. Antibiotics prescribed to our patients had high oral bioavailability and bone diffusion with rifampicin/fluoroquinolone combinations being the most frequent antibiotic regimens. Both hospital stay and intravenous antibiotic treatment mean durations were shorter in the before group than in the after group [15.0 versus 11.0 days; (P < 0.01) and 13.0 versus 7.0 days; P < 0.001, respectively]. The remission rate assessed after at least a year of follow-up was comparable in the before and the after groups (hazard ratio = 0.70; 95% CI 0.30-1.58). CONCLUSIONS Full oral targeted antibiotic therapy using a drug regimen with high oral bioavailability and good bone diffusion is an option for the treatment of patients with GPC-related PJIs.
Collapse
Affiliation(s)
| | - Olivier Robineau
- Gustave Dron Hospital, 59200 Tourcoing, France.,Univ. Lille, F-59000 Lille, France.,University Hospital of Lille, 59037 Lille Cedex, France.,French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Marie Titecat
- French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Nicolas Blondiaux
- French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Hervé Dezeque
- French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | | | - Caroline Loiez
- French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Sophie Putman
- French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Eric Beltrand
- French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Henri Migaud
- Univ. Lille, F-59000 Lille, France.,University Hospital of Lille, 59037 Lille Cedex, France.,French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| | - Eric Senneville
- Gustave Dron Hospital, 59200 Tourcoing, France.,Univ. Lille, F-59000 Lille, France.,University Hospital of Lille, 59037 Lille Cedex, France.,French National Reference Centre for Complex Osteo-Articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group)
| |
Collapse
|
10
|
Meybeck A, Huleux T, Tétart M, Thill P, Derdour V, Bocket L, Alidjinou E, Patoz P, Robineau O, Ajana F. Le fardeau de la COVID-19 chez les personnes vivant avec le VIH après la première vague de la pandémie. Infect Dis Now 2021. [PMCID: PMC8327515 DOI: 10.1016/j.idnow.2021.06.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Introduction Un nouveau coronavirus, le SARS-CoV-2 est apparu à Wuhan en Chine fin décembre 2019. Il est responsable d’infections respiratoires, pouvant mener à un syndrome de détresse respiratoire aigu (SDRA) et au décès. Ce virus s’est rapidement répandu dans le monde. En France, les premiers cas ont été diagnostiqués fin janvier 2020. Un confinement national a été mis en place de mars à avril 2020 pour tenter de contenir l’épidémie. L’objectif de notre étude était de déterminer le poids de la COVID-19 chez les personnes vivant avec le VIH (PVVIH) après la première vague de la pandémie. Matériels et méthodes Nous avons réalisé une enquête épidémiologique du 1er avril au 1er août 2020 dans un centre de référence pour la prise en charge des PVVIH. Lors de leur première visite de suivi après la levée du confinement, les PVVIH ont rempli un questionnaire sur les facteurs d’exposition et les symptômes compatibles avec la COVID-19. Une sérologie SRAS-CoV-2 était prélevée lors de la consultation. La prévalence, l’incidence et les facteurs de risque de la COVID-19 chez les PVVIH ont été déterminés. Résultats Six cent PVVIH ont été inclus. Une infection à SARS-CoV-2 était confirmée chez 16 d’entre eux. Les symptômes compatibles avec la COVID-19 étaient fréquents chez les PVVIH en présence ou non d’une infection confirmée à SARS-CoV-2 (67 % vs 32 %, p = 0,02). Parmi les PVVIH ayant présenté une infection à SARS-CoV-2 confirmée, une (6 %) a été hospitalisée, 5 (31 %) sont restées asymptomatiques. Il n’y avait pas de différence concernant l’âge, le sexe, les comorbidités associés, et les variables liées à l’infection par le VIH entre les PVVIH ayant ou non contracté la COVID-19. Seul un contact rapproché avec une personne infectée par le SARS-CoV-2 était associé à l’acquisition de la COVID-19 (40 % vs 13 %, p = 0,01). La prévalence de la COVID-19 chez les PVVIH était de 2,5 %, la moitié de celle observée dans la population générale après la première vague de la pandémie en France. L’incidence était estimée à 0,16 pour 100 patients/semaine. Conclusion La prévalence de la COVID-19 chez les PVVIH était 2 fois moindre que celle observée dans la population générale. Seul un contact rapproché avec une personne infectée par le SARS-CoV-2 était associé à l’acquisition de la COVID-19. La proportion d’infections à SARS-CoV-2 asymptomatiques était élevée chez les PVVIH.
Collapse
|
11
|
Argy N, Bertin G, Milet J, Hubert V, Clain J, Cojean S, Houzé P, Tuikue-Ndam N, Kendjo E, Deloron P, Houzé S, Matheron S, Casalino E, Wolff M, Delaval A, Agnamey P, Durand R, Pilo J, Rapp C, Faucher J, Cuisenier B, Poilane I, Bemba D, Roide A, Debourgogne A, Thibault M, Toubas D, Patoz P, De Gentile L, Pons D, Hurst J, Lohmann C, Bigel M, Godineau N, Thouvenin M, Dunand J, Ait-Ammar N, Angoulvant A, Dahane N, Lefevre M, Murat J, Garnaud C, Dannaoui E, Botterel F, Dutoit E, Dardé M, Ichou H, Branger C, Penn P, Angebault C, Morio F, Bret L, Thellier M, Mouri O, Cateau E, Siriez J, Fenneteau O, Revest M, Belaz S, Belkadi G, Hamane S, Bretagne S, Aboubacar A, Leloup G, Develoux M, Lapillonne H, Eloy O, Nevez G, Raffenot D, Buret B, Desoubeaux G, Goepp A. Preferential expression of domain cassettes 4, 8 and 13 of Plasmodium falciparum erythrocyte membrane protein 1 in severe malaria imported in France. Clin Microbiol Infect 2017; 23:211.e1-211.e4. [DOI: 10.1016/j.cmi.2016.10.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Revised: 10/06/2016] [Accepted: 10/12/2016] [Indexed: 11/25/2022]
|
12
|
Deconinck L, Meybeck A, Patoz P, Van Grunderbeeck N, Boussekey N, Chiche A, Delannoy PY, Georges H, Leroy O. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Infect Dis (Lond) 2017; 49:396-404. [DOI: 10.1080/23744235.2016.1277035] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Affiliation(s)
- Laurène Deconinck
- Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
| | - Agnès Meybeck
- Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
| | - Pierre Patoz
- Laboratoire de microbiologie, Centre Hospitalier de Tourcoing, Tourcoing, France
| | | | - Nicolas Boussekey
- Service de réanimation, Centre Hospitalier de Tourcoing, Tourcoing, France
| | - Arnaud Chiche
- Service de réanimation, Centre Hospitalier de Tourcoing, Tourcoing, France
| | | | - Hugues Georges
- Service de réanimation, Centre Hospitalier de Tourcoing, Tourcoing, France
| | - Olivier Leroy
- Service de réanimation, Centre Hospitalier de Tourcoing, Tourcoing, France
| |
Collapse
|
13
|
Pasquet A, Robineau O, D’Elia P, Valette M, Vandamme S, Patoz P, Leroy O, Voitot J, Senneville E. IAS-01 - Caractéristiques et pronostic des patients atteints d’une infection de prothèse vasculaire (IPV) suivie par émission de positons (TEP) : une cohorte prospective de 67 patients. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30398-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Deconinck L, Meybeck A, Pradier M, Patoz P, Melliez H, Senneville E. Community acquired fungemia caused by Candida pulcherrima: diagnostic contribution of MALDI-TOF mass spectrometry. Ann Clin Microbiol Antimicrob 2016; 15:14. [PMID: 26951431 PMCID: PMC4782459 DOI: 10.1186/s12941-016-0129-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 02/29/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Community-onset candidemia constitute a distinct clinical entity the incidence of which is increasing. Contribution of non-albicans Candida species is rising. CASE PRESENTATION We describe here the first reported case of community acquired fungemia due to Candida pulcherrima. Identification to the species level was performed by MALDI-TOF mass spectrometry. Treatment with fluconazole was successful. CONCLUSION This case confirms the pathogenic role of C. pulcherrima and the contribution of MALDI-TOF mass spectrometry for identification of rare Candida species.
Collapse
Affiliation(s)
- Laurène Deconinck
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Agnès Meybeck
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Maxime Pradier
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Pierre Patoz
- Laboratoire de biologie, Centre Hospitalier Dron, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Hugues Melliez
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Eric Senneville
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| |
Collapse
|
15
|
Robert J, Pantel A, Merens A, Lavigne JP, Nicolas-Chanoine MH, Brieu N, Vrain A, Scanvic A, Porcheret H, Garnier P, Bertrand X, Descamps D, Hombrouck C, Soullie B, Heym B, de Montclos H, Garrec H, Levast M, Mendes-Martins L, Decousser JW, Huet C, Bert F, Herzig V, Klein JP, Nebbad B, Hendricx S, Verhaeghe A, Lafaurie C, Lanselle C, Elsayed F, Carrer A, Drieux-Rouzet L, Evreux F, Varache C, Wallet F, Martin C, Le-Bris JM, Moulhade MC, Deville E, Menouni O, Jean-Pierre H, Pierrot P, Delarbre JM, Coude B, Foca M, Degand N, Prots L, Pantel A, Adam MN, Laurens E, Raskine L, Laouira S, Arlet G, Sanchez R, Peuchant O, Grau V, Laurent C, De-Champs C, Vachee A, Harriau P, Merens A, Belmonte O, Michel G, Henry C, Picot S, Glatz I, Gueudet T, Honderlick P, Cavalie L, Galinier JL, Patoz P, van-der-Mee-Marquet N, Haguenoer E, Canis F, Kassis-Chikhany N, Le-Garrec Y. Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12. J Antimicrob Chemother 2014; 69:2706-12. [DOI: 10.1093/jac/dku208] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
16
|
Alfandari S, Gois J, Delannoy PY, Georges H, Boussekey N, Chiche A, Meybeck A, Patoz P, Blondiaux N, Senneville E, Melliez H, Leroy O. Management and control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. Med Mal Infect 2014; 44:229-31. [PMID: 24840286 DOI: 10.1016/j.medmal.2014.03.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2014] [Revised: 03/23/2014] [Accepted: 03/24/2014] [Indexed: 10/25/2022]
Abstract
OBJECTIVE We had for aim to describe the identification and management of a 14-clonal carbapenem-resistant Acinetobacter baumannii (CRAB) outbreak, following admission of a known CRAB-infected patient in an ICU. METHODS We reviewed the carriers' files and outbreak management procedures. RESULTS The index patient was admitted with strict isolation precautions. The outbreak started 2 months after his discharge. It persisted despite reinforcement of strict isolation precautions, staff and patient cohorting, and extensive environmental decontamination including 2 rounds of routine terminal cleaning and disinfection or 1 round of cleaning and disinfection followed by hydrogen peroxide treatment. A second epidemic peak, after 4 weeks without any case, led to another wide environmental sampling and decontamination rounds. The source of the CRAB outbreak was suspected to be the blood pressure cuffs Velcro. Switching to cuffs submersible in a disinfectant stopped the outbreak. CONCLUSIONS CRAB outbreaks are difficult to manage and sources of persistent colonization can be unexpected.
Collapse
Affiliation(s)
- S Alfandari
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France.
| | - J Gois
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - P-Y Delannoy
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - H Georges
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - N Boussekey
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - A Chiche
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - A Meybeck
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - P Patoz
- Laboratoire de biologie, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - N Blondiaux
- Laboratoire de biologie, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - E Senneville
- Service universitaire des maladies infectieuses et du voyageur, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - H Melliez
- Service universitaire des maladies infectieuses et du voyageur, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - O Leroy
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| |
Collapse
|
17
|
Sabau L, Meybeck A, Gois J, Devos P, Patoz P, Boussekey N, Delannoy PY, Chiche A, Georges H, Leroy O. Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors. Infection 2013; 42:23-30. [PMID: 23780568 DOI: 10.1007/s15010-013-0492-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2013] [Accepted: 05/31/2013] [Indexed: 01/18/2023]
Abstract
PURPOSE We assessed factors associated with mortality and complicated course in the case of Clostridium difficile infection (CDI) acquired in the intensive care unit (ICU). METHOD Retrospective cohort study conducted from 1 January 2002 through 1 January 2012. All patients who acquired CDI in our ICU were included. RESULTS Thirty-one patients were included. Twenty patients (65 %) had mild colitis, 8 (25 %) moderate colitis, and 3 (10 %) severe colitis. Initial antibiotherapy was metronidazole (n = 30, 97 %) and vancomycin (n = 1, 3 %). Seventeen patients (55 %) experienced at least one complication: failure of initial treatment (n = 16, 52 %), shock (n = 11, 34 %), need for surgery (n = 1, 3 %) or renal replacement (n = 4, 13 %), or death (n = 8, 26 %). Risk factors of ICU mortality were history of corticosteroids prescription, prolonged ICU stay, low serum albumin level, and high Sequential Organ Failure Assessment (SOFA) score at the time of CDI diagnosis. Factors associated with a complicated course were high Simplified Acute Physiology Score (SAPS II), high SOFA score, and low serum albumin level at the time of CDI onset. CONCLUSION Risk factors of poor outcome in patients with CDI acquired in the ICU are different from those in the general population suffering from CDI. The implementation of treatment algorithms taking into account these factors may reduce complication rates in this specific population.
Collapse
Affiliation(s)
- L Sabau
- Service de Réanimation et Maladies Infectieuses, Hôpital Dron, 128 avenue du Président Coty, 59200, Tourcoing, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Gharbi M, Flegg JA, Hubert V, Kendjo E, Metcalf JE, Bertaux L, Guérin PJ, Le Bras J, Aboubaca A, Agnamey P, Angoulvant A, Barbut P, Basset D, Belkadi G, Bellanger AP, Bemba D, Benoit-Vica F, Berry A, Bigel ML, Bonhomme J, Botterel F, Bouchaud O, Bougnoux ME, Bourée P, Bourgeois N, Branger C, Bret L, Buret B, Casalino E, Chevrier S, Conquere de Monbrison F, Cuisenier B, Danis M, Darde ML, De Gentile L, Delarbre JM, Delaunay P, Delaval A, Desoubeaux G, Develoux M, Dunand J, Durand R, Eloy O, Fauchet N, Faugere B, Faye A, Fenneteau O, Flori P, Fontrouge M, Garabedian C, Gayandrieu F, Godineau N, Houzé P, Houzé S, Hurst JP, Ichou H, Lachaud L, Lebuisson A, Lefevre M, LeGuern AS, Le Moal G, Lusina D, Machouart MC, Malvy D, Matheron S, Maubon D, Mechali D, Megarbane B, Menard G, Millon L, Aiach MM, Minodier P, Morelle C, Nevez G, Parola P, Parzy D, Patey O, Patoz P, Penn P, Perignon A, Picot S, Pilo JE, Poilane I, Pons D, Poupart M, Pradines B, Raffenot D, Rapp C, Receveur MC, Sarfati C, Senghor Y, Simon F, Siriez JY, Taudon N, Thellier M, Thouvenin M, Toubas D. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malar J 2013; 12:35. [PMID: 23351608 PMCID: PMC3583707 DOI: 10.1186/1475-2875-12-35] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 01/19/2013] [Indexed: 11/10/2022] Open
Abstract
Background Chloroquine (CQ) was the main malaria therapy worldwide from the 1940s until the 1990s. Following the emergence of CQ-resistant Plasmodium falciparum, most African countries discontinued the use of CQ, and now promote artemisinin-based combination therapy as the first-line treatment. This change was generally initiated during the last decade in West and Central Africa. The aim of this study is to describe the changes in CQ susceptibility in this African region, using travellers returning from this region as a sentinel system. Methods The study was conducted by the Malaria National Reference Centre, France. The database collated the pfcrtK76T molecular marker for CQ susceptibility and the in vitro response to CQ of parasites from travellers’ isolates returning from Senegal, Mali, Ivory Coast or Cameroon. As a proxy of drug pressure, data regarding CQ intake in febrile children were collated for the study period. Logistic regression models were used to detect trends in the proportions of CQ resistant isolates. Results A total of 2874 parasite isolates were genotyped between 2000–2011. The prevalence of the pfcrt76T mutant genotype significantly decreased for Senegal (from 78% to 47%), Ivory Coast (from 63% to 37%), Cameroon (from 90% to 59%) and remained stable for Mali. The geometric mean of the 50% inhibitory concentration (IC50) of CQ in vitro susceptibility and the proportion of resistant isolates (defining resistance as an IC50 value > 100 nM) significantly decreased for Senegal (from 86 nM (59%) to 39 nM (25%)), Mali (from 84 nM (50%) to 51 nM (31%)), Ivory Coast (from 75 nM (59%) to 29 nM (16%)) and Cameroon (from 181 nM (75%) to 51 nM (37%)). Both analyses (molecular and in vitro susceptibility) were performed for the 2004–2011 period, after the four countries had officially discontinued CQ and showed an accelerated decline of the resistant isolates for the four countries. Meanwhile, CQ use among children significantly deceased in this region (fixed effects slope = −0.3, p < 10-3). Conclusions An increase in CQ susceptibility following official withdrawal of the drug was observed in travellers returning from West and Central African countries. The same trends were observed for molecular and in vitro analysis between 2004-2011and they correlated to the decrease of the drug pressure.
Collapse
Affiliation(s)
- Myriam Gharbi
- Mère et enfant face aux infections tropicales, IRD unité mixte de recherche 216, Université Paris Descartes-Paris V, 4 avenue de l'Observatoire, Paris Cedex 06 75270, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Lequerré T, Vittecoq O, Saugier-Veber P, Goldenberg A, Patoz P, Frébourg T, Le Loët X. A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford) 2006; 46:709-14. [PMID: 17178739 DOI: 10.1093/rheumatology/kel399] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE Describe four generations (11 members) of a family with a cryopyrin-associated periodic syndrome (CAPS), including joint destruction, associated with a CIAS1-gene mutation and good responses to anakinra. METHODS In addition to detailed questioning and physical examination, six family members underwent haematological, immunological and biochemical testing. Exon 3 of the CIAS1 gene was sequenced in search of a mutation in the 1q44 region. RESULTS During childhood or adolescence, four family members developed different combinations of the following CAPS manifestations: deafness (3/4); arthritis (4/4) with joint destruction for two of them; nervous (cerebral demyelinization, 2/4), cutaneous (livedo and/or urticaria, 3/4) and eye lesions (episcleritis and/or papilloedema, 4/4); IgA hypergammaglobulinaemia (4/4) and inflammatory syndrome (3/4). Sequencing of six family members' CIAS1-gene exon 3 identified a heterozygous mutation, c.1043C > T. Pertinently, this CAPS is distinct from chronic infantile neurological cutaneous and arthritis syndrome/neonatal onset multisystemic inflammatory disease syndrome and Muckle-Wells syndrome (MWS), which also result from exon 3 mutations in this gene. Moreover, this family did not have the usual neurological manifestations, typical morphological features and frequent amyloidosis of MWS. CONCLUSIONS We describe a previously unreported form of CAPS with atypical neurological signs, joint destruction and livedo. This observation extends the clinical spectrum associated with CIAS1 mutations. Anakinra, an interleukin-1-receptor antagonist, prescribed to two family members, was highly effective.
Collapse
Affiliation(s)
- T Lequerré
- Department of Rheumatology, Rouen University Hospital, 76031 Rouen, Cedex, France.
| | | | | | | | | | | | | |
Collapse
|
20
|
Eulry F, Chevalier X, Crozes P, Lechevalier D, Magnin J, Prudat M, Patoz P, Larget-Piet B. [Plasma lipids in reflex sympathetic dystrophy. A study apropos of 90 cases]. Rev Rhum Mal Osteoartic 1992; 59:721-7. [PMID: 1306590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Plasma levels of cholesterol, triglyceride, HDL-cholesterol, and apolipoproteins A1 and B were assayed in ninety patients (sixty-four male and twenty-six female) with reflex sympathetic dystrophy and in ninety controls matched for age, sex, and body mass index (BMI). No significant differences were found between the two groups for the proportions of patients with increased plasma cholesterol levels (6.6% versus 4.4%) or increased plasma triglyceride levels (40% versus 30%), as defined by Turpin's age and sex-specific criteria, or for mean values of these parameters. In the 38 patients with reflex sympathetic dystrophy of less than 3.5 months duration, plasma triglyceride levels were significantly higher than in the 38 matched controls (1.24 + 0.57 g/l versus 1.02 +/- 0.91; p = 0.04). In patients (n = 52) with disease of more than four months duration (range 4-39), plasma triglyceride levels were similar in the two groups. Lipidemia was similar in patients and controls regardless of age, sex, topography of the disease, clinical manifestations, and whether or not the disease was due to an injury. This study, in contrast to previous reports, failed to disclose an association between reflex sympathetic dystrophy and hyperlipidemia. Transient hypertriglyceridemia may occur during the first 3 1/2 months of the disease as a result of initial immobilization.
Collapse
Affiliation(s)
- F Eulry
- Service de Rhumatologie, Hôpital d'Instruction des Armées Begin, Saint-Mandé
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Gourmelen O, Le Loet X, Daragon A, Patoz P. [Meningo-radiculitis in Lyme disease resistant to penicillin G]. Presse Med 1989; 18:584. [PMID: 2523059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|